Strengthening synapses

Syndesi Therapeutics S.A. is developing SV2A modulators to improve cognitive function in a range of indications including mild-to-moderate Alzheimer’s disease by regulating a broader sweep of neurotransmitters than available therapies.

Cognitive impairment in AD stems from progressive decline in synaptic function. In late-stage disease, a large portion of synapses are lost altogether. AChE inhibitors, which enhance levels of neurotransmitter acetylcholine (ACh) in the synaptic cleft of AD patients, are standard of care in patients at all stages of disease to treat cognitive symptoms such as dementia and agitation...